US-based biopharmaceutical firm VBI Vaccines (VBI) and GlaxoSmithKline Biologicals (GSK) have entered into a research collaboration to evaluate VBI’s LPV Platform, which helps in the development of vaccines and biologics with improved stability and preserved potency.

Financial and further terms of the collaboration were not disclosed by both the companies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, which is aimed at enhancing vaccine stability, GSK has the option to negotiate an exclusive license to VBI’s LPV Platform for use in a defined field.

According to VBI, stability is a critical issue potentially affecting vaccine potency, safety and ultimately patient access.

"We’re thrilled to be working with GlaxoSmithKline, a leading global healthcare company, to explore the potential of the LPV technology to their pipeline."

The LPV platform uses a formulation and process to enclose and protect the antigen (active component) of a vaccine or biologic.

See Also:

VBI president and CEO Jeff Baxter said: "With our partners, we seek to develop a next generation of vaccines and biologics with improved stability characteristics that allow for consistently safe and effective administration in both established and emerging markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We’re thrilled to be working with GlaxoSmithKline, a leading global healthcare company, to explore the potential of the LPV technology to their pipeline. This collaboration further validates the significant potential of our LPV Platform."

So far, the US firm has completed proof of concept studies on a number of vaccine and biologic targets that show the LPV Platform’s ability to preserve potency under stress conditions.

VBI is focused on developing new technologies that seek to expand vaccine protection in large underserved markets and its eVLP Platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus.

Glaxosmithkline Biologicals researches, develops, manufactures and supplies vaccines, which are used to tackle various diseases such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B.